title: Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease.
abstract: Allogeneic bone marrow transplantation is limited by the availability of suitable marrow donors and risk of graft-versus-host disease (GVHD) and opportunistic infection. In an attempt to ameliorate these limitations, umbilical cord blood has been postulated as an alternative source of allogeneic haemopoietic stem cells for transplantation. From September, 1994, umbilical cord blood from sibling donors has been used to reconstitute haemapoiesis in 44 children with acquired or congenital lympho-haemapoietic disorders, neuroblastoma, or metabolic diseases. Patients who had HLA-identical and HLA-1 antigen disparate grafts, had a probability of engraftment at 50 days after transplantation of 85%. No patient had late graft failure. The probability of grade II-IV GVHD at 100 days was 3% and the probability of chronic GVHD at one year was 6%. With a median follow-up of 1.6 years, the probability of survival for recipients of HLA-identical or HLA-1 antigen disparate grafts is 72%. We conclude that umbilical cord blood is a sufficient source of transplantable haemopoietic stem cells for children with HLA-identical or HLA-1 antigen disparate sibling donors with very low risk of acute or extensive chronic GVHD. The feasibility of umbilical-cord-blood transplantation with HLA-2 and HLA-3 antigen disparate sibling donors remains to be determined.
authors.affiliation: Department of Pediatrics, University of Minnesota, School of Medicine, Minneapolis 55455, USA.
authors.forename: J E
authors.initials: JE
authors.lastname: Wagner
authors.forename: N A
authors.initials: NA
authors.lastname: Kernan
authors.forename: M
authors.initials: M
authors.lastname: Steinbuch
authors.forename: H E
authors.initials: HE
authors.lastname: Broxmeyer
authors.forename: E
authors.initials: E
authors.lastname: Gluckman
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D005312:Fetal Blood / Q000166:cytology*; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology; D006402:Hematologic Diseases / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D008297:Male; D008659:Metabolic Diseases / Q000401:mortality / Q000628:therapy*; D009447:Neuroblastoma / Q000401:mortality / Q000628:therapy*; D011336:Probability; D012801:Sibling Relations; D015996:Survival Rate; D014184:Transplantation, Homologous